{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rabeprazole&page=2",
    "query": {
      "intervention": "Rabeprazole",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rabeprazole&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T02:02:35.239Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01286194",
      "title": "A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Frequent Heartburn"
      ],
      "interventions": [
        {
          "name": "Rabeprazole sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1500,
      "start_date": "2006-04",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2011-01-31",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 33,
      "location_summary": "Scottsdale, Arizona • Griffin, Georgia • Lawrenceville, Georgia + 29 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Griffin",
          "state": "Georgia"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Kansas Ciry",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01286194"
    },
    {
      "nct_id": "NCT03130556",
      "title": "A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Glasdegib",
          "type": "DRUG"
        },
        {
          "name": "High Fat, High Calorie Meal",
          "type": "OTHER"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2017-05-01",
      "completion_date": "2017-07-21",
      "has_results": false,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03130556"
    },
    {
      "nct_id": "NCT07597928",
      "title": "A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adults",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-08049820",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-05-13",
      "completion_date": "2026-09-25",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07597928"
    },
    {
      "nct_id": "NCT00747526",
      "title": "A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease (GERD)"
      ],
      "interventions": [
        {
          "name": "Rabeprazole sodium 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole sodium 10 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "11 Months",
        "sex": "ALL",
        "summary": "1 Month to 11 Months"
      },
      "enrollment_count": 51,
      "start_date": "2007-12",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2013-07-08",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 13,
      "location_summary": "Little Rock, Arkansas • Oakland, California • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00747526"
    },
    {
      "nct_id": "NCT07171619",
      "title": "Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Nirogacestat",
          "type": "DRUG"
        },
        {
          "name": "Nirogacestat and Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Nirogacestat and Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2025-08-21",
      "completion_date": "2025-11-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07171619"
    },
    {
      "nct_id": "NCT04211545",
      "title": "Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        },
        {
          "name": "CC-92480",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-10-21",
      "completion_date": "2019-12-26",
      "has_results": false,
      "last_update_posted_date": "2020-05-08",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04211545"
    },
    {
      "nct_id": "NCT05571787",
      "title": "HMPL-523 Food Effect and Proton Pump Inhibitor Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Lymphoma"
      ],
      "interventions": [
        {
          "name": "HMPL-523",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 26,
      "start_date": "2022-07-13",
      "completion_date": "2022-09-22",
      "has_results": false,
      "last_update_posted_date": "2023-02-23",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05571787"
    },
    {
      "nct_id": "NCT05918822",
      "title": "A Study of Maribavir Pediatric Formulation in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Maribavir Commercial Tablet Formulation",
          "type": "DRUG"
        },
        {
          "name": "Maribavir Pediatric Powder-for-oral Suspension Formulation",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2023-07-25",
      "completion_date": "2023-09-01",
      "has_results": true,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05918822"
    },
    {
      "nct_id": "NCT02655614",
      "title": "A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "GDC-0134",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Caffeine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2016-05-31",
      "completion_date": "2020-03-16",
      "has_results": false,
      "last_update_posted_date": "2020-08-06",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02655614"
    },
    {
      "nct_id": "NCT04510649",
      "title": "Surufatinib DDI With a PPI and a CYP3A Inducer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Part A",
          "type": "DRUG"
        },
        {
          "name": "Part B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchison Medipharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2020-07-09",
      "completion_date": "2021-03-02",
      "has_results": false,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-09-24T02:02:35.239Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04510649"
    }
  ]
}